300529 Jafron Biomedical
- 28.93
- +0.13+0.45%
Jafron Biomedical News
Jianfan Biology (300529): The trend of optimizing internal and external ecology and improving management is expected to continue
Introduction to this report: The external policy environment and internal team ecology were improved in Q1 2024. The performance exceeded expectations, and the management improvement trend is expected to continue. Maintain an increase in holdings rating. Key investment points: Maintain an increase in holdings rating. Consider the external policy environment and internal
Jianfan Biotech (300529): Business performance, Liu Dian, Huaming, innovation and promotion have stepped up
The investment logic experienced a period of poor performance and is expected to rise at an inflection point in the future. As a leader in the domestic hemoperfusion device industry, the company experienced a continuous high sales revenue growth rate of more than 30% and profit growth of more than 35% for 5 consecutive years until 2021
Jianfan Biotech (300529): 24Q1 performance improved drastically, fundamentals reversed, inflection point reached
Event: The company released its 2023 annual report and 2024 quarterly report. (1) 2023 Annual Report: In 2023, the company achieved operating income of 1.922 billion yuan, a year-on-year decrease of 22.84%; net profit to mother 4.36
Jianfan Biotech (300529): 1Q24's performance returned to rapid growth
The 1Q24 company has returned to a rapid development path and maintained that the “buy” rating company achieved revenue/net profit of 1.92 billion yuan (yoy -22.8%/-50.9%) in 23 years, which is lower than our expectations (estimated revenue)
Jianfan Biotech (300529): Channel inventory improved, performance resumed growth
Incident: The company released its 2023 annual report, achieving operating income of 1.92 billion yuan, a year-on-year decrease of 22.8%; realized net profit attributable to shareholders of the parent company of 400 million yuan, a year-on-year decrease of 50.9%; and realized net profit attributable to mother after deduction 4.
Jianfan Biotech (300529.SZ): Net profit of 285 million yuan in the first quarter increased by 44.90% year-on-year
Gelonghui, April 25, 丨 Jianfan Biotech (300529.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 744 million yuan, up 30.00% year on year; net profit attributable to shareholders of listed companies was 285 million yuan, up 44.90% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 271 million yuan, up 42.74% year on year; basic earnings per share were 0.3512 yuan.
Jianfan Biotech (300529): First-quarter results resumed high growth and domestic and foreign product development progressed smoothly
On April 25, 2024, the company released the 2023 Annual Report and the 2024 First Quarter Report. In 2023, the company achieved revenue of 1,922 million yuan, -23% year-on-year; net profit to mother of 436 million yuan
Jianfan Biology (300529): At the end of the journey of thorns, the road to prosperity can still be expected
Industry trends: Hemoperfusion is in line with the development trend of blood purification, and clinical superiority has been fully proven. Although the company's performance has fluctuated in recent years due to a series of external factors, we believe that its technology itself is advanced and in line with industry development
Jianfan Biotech (300529.SZ): It has production bases in Zhuhai, Beijing, Tianjin, Hubei and other places
Gelonghui March 15 丨 Jianfan Biotech (300529.SZ) said on the investor interactive platform that the company has production bases in Zhuhai, Beijing, Tianjin, Hubei and other places.
Express News | Jianfan Biotech: Participated in volume procurement of hemodialysis medical consumables by the Inter-provincial Alliance
Jianfan Biology (300529.SZ): Currently, the company's channel inventory situation is at a healthy level
Gelonghui March 12 丨 Jianfan Biotech (300529.SZ) was surveyed by a specific target on March 8, 2024, and asked “the current channel inventory situation?” The company replied that qualitatively speaking, the company's channel inventory situation is currently at a healthy level.
Jianfan Biology (300529.SZ): Up to now, nephrology products have covered more than 6,000 hospitals, and hepatology products have covered more than 2,000 hospitals
Gelonghui March 12 丨 Jianfan Biotech (300529.SZ) was surveyed by specific subjects on March 8, 2024, on “What is the hospital coverage of the company's products?” The company replied that up to now, nephrology products have covered more than 6,000 hospitals, and hospitals that can perform dialysis treatment have basically been covered. Hepatology products cover more than 2,000 hospitals, and critical care products cover more than 1,600 hospitals (hepatology and critical care are mainly in tertiary hospitals). Next, the company will focus on improving clinical use in hospitals already covered.
Jianfan Biotech (300529): Launched the “Double Improvement of Quality and Return” Program, a domestic leader in blood perfusion to promote high-quality global development
Event: The company released the “Double Improvement of Quality and Return” action plan to promote the company's long-term healthy and sustainable development. Focus on the blood purification market and benefit patients with advanced treatment technology with clinical efficacy and superiority. Currently, Jianfan HA series
Jianfan Biotech (300529.SZ) has repurchased 2.18% of shares at a cost of 342 million yuan
Jianfan Biotech (300529.SZ) announced that as of February 29, 2024, the company is using centralized bidding transactions...
A-share changes丨Jianfan Biotech surged for 2 consecutive days, and some products obtained EU MDR certification
Gelonghui Feb. 7 | Jianfan Biotech (300529.SZ) once again boosted by more than 9%. The two-day increase was as high as 20%. The stock price returned to 20 yuan, with a total market value of 16.2 billion yuan. The company recently received a notice from the EU Notified Body that the company's products disposable hemoperfusion devices (HA series) and disposable plasma bilirubin adsorbers (BS series) have obtained EU MDR certification issued in accordance with the EU Medical Devices Regulation (EU) 2017/745 (“MDR”), and can be recognized by the EU in EU countries and other countries
Jianfan Biotech (300529.SZ) has obtained EU MDR certification for some products
Jianfan Biotech (300529.SZ) issued an announcement. The company recently received a notice from the EU Notified Body. The company's product 1...
Jianfan Biotech (300529.SZ) has repurchased 2.13% of shares at a cost of 336 million yuan
Jianfan Biotech (300529.SZ) announced that as of January 31, 2024, the company will use centralized bidding transactions...
Jianfan Biotech (300529.SZ) has repurchased a total of 1.01% of its shares at a cost of 172 million yuan
Jianfan Biotech (300529.SZ) announced that as of January 23, 2024, the company is using centralized bidding transactions...
Jianfan Biotech (300529.SZ): 2023 net profit pre-reduced by 45%-62%
Gelonghui, January 19 | Jianfan Biotech (300529.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 340 million yuan to 490 million yuan, down 62% to 45% from the same period last year; net profit profit after deducting non-recurring profit and loss was 312 million yuan to 462 million yuan, down 62% to 44% from the same period last year. During the reporting period, due to factors such as fluctuations in industry demand and year-on-year declines in the prices of some of the company's products, the current operating income and product gross margin declined year-on-year. At the same time, the decline in the company's product production led to product production
Jianfan Biology (300529.SZ): Currently, it has two hemodialyzer production lines with mass production capacity
Glonghui December 15: Some investors asked Jianfan Biotech (300529.SZ) on the investor interactive platform, “How is the progress of the company's dialyzer production line? Can dialysis membranes be produced, and polyether wire drawing technology is available?” The company replied, “(1) The company currently has two hemodialyzer production lines and has mass production capacity. The company's homemade membrane material is polyethersulfone, which is currently in the R&D registration stage. (2) In September 2023, the company was selected as a finalist for the first batch of biomedical materials innovation tasks by the Ministry of Industry and Information Technology. It is the only unit in Guangdong Province to be shortlisted for the development of medical polyethersulfone polymer materials. raw
Analysis
Price Target
No Data
